This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion
by Zacks Equity Research
We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.
Pfizer's Mylotarg Recommended by FDA Advisory Committee
by Zacks Equity Research
Pfizer Inc. (PFE) announced that the FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of Mylotarg for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).
Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label
by Zacks Equity Research
Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.
J&J (JNJ) to Commence Pharma Q2 Earnings Season: What's Up?
by Zacks Equity Research
Johnson & Johnson (JNJ), a healthcare bellwether, will report second-quarter 2017 results on Jul 18.
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx
by Zacks Equity Research
Exelixis (EXEL) initiated a phase III trial, CheckMate 9ER to evaluate Opdivo in combination with Cabometyx or Opdivo and Yervoy in combination with Cabometyx versus Sutent in patients with RCC.
Arena's Ralinepag Positive in Phase II PAH Study, Shares Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) shares surged 41.3% in after-market trading on Monday after its phase II study evaluating its key pipeline candidate, ralinepag, in pulmonary arterial hypertension, met the primary endpoint.
Lilly's Breast Cancer Drug Gets Priority Review Status by FDA
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.
Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 in combination with Xeloda for treatment of third-line HER2-positive metastatic breast cancer.
Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook
by Arpita Dutt
3 studies on Merck's (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.
Pfizer's (PFE) Leukemia Candidate Receives Approval in EU
by Zacks Equity Research
Pfizer Inc. (PFE) announced that its leukemia candidate, Besponsa, has been approved by the European Commission.
Why is Corcept's Stock Up More Than 60% So Far This Year?
by Zacks Equity Research
Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.
Arena Ends Study on Extended Release Formulation of PAH Drug
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.
Sarepta Looks to Focus on Exondys 51 & DMD Pipeline in 2017
by Zacks Equity Research
We issued an updated research report on Cambridge, MA-based Sarepta Therapeutics, Inc. (SRPT) on Jun 28.
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca
M&As, Rich Pipelines & Catalyst Rich 2017 to Drive Pharma Stocks
by Arpita Dutt
The biotech sector's fundamentals remain strong.
Merck's CETP Inhibitor Reduces CV Risk in Phase III Study
by Zacks Equity Research
Merck & Co., Inc. (MRK) announced that a large late-stage cardiovascular outcomes study (REVEAL) evaluating anacetrapib, a cholesterol-lowering medicine, met the primary endpoint by reducing cardiovascular (CV) risk.
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
by Zacks Equity Research
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
Epizyme Progressing Well on Two Lead Pipeline Candidates
by Zacks Equity Research
We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
by Eric Dutram
This podcast takes a closer look at the world of cancer research, and in particular, that of immunotherapy. I have guest Brad Loncar on to discuss this market and a few promising candidates to watch in this area, check it out for more info on this interesting biotech segment!
Stock Market News for June 22, 2017
by Zacks Equity Research
Energy shares continued to decline on Wednesday, sending the Dow and the S&P 500 lower
Merck's Keytruda on a Roll: Can it Retain the Momentum?
by Zacks Equity Research
As demand for immuno-oncology drugs and their combinations rises, Merck & Co., Inc.'s (MRK) anti-PD-1 therapy, Keytruda, is being touted as a significant top-line driver for this Kenilworth, NJ based pharma giant.
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
by Zacks Equity Research
Shire Plc (SHPG) announced that the FDA has approved its new attention deficit hyperactivity disorder (ADHD) drug, Mydayis (mixed salts of a single-entity amphetamine product) in patients 13 years and older
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
by Zacks Equity Research
The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
by Zacks Equity Research
Exelixis, Inc. (EXEL) announced results from an analysis of the data from the phase II trial, CABOSUN evaluating Cabometyx to Sutent for kidney cancer.